GLP-1 receptor agonist/en: Difference between revisions

Line 3:

{{Short description|Agonist of the GLP-1 receptor used in the treatment of type 2 diabetes}}

{| class="wikitable sortable" style="width:100%"

|-

!一般名

!先発名

!class="unsortable"| 日本

!創薬/開発

!備考

|-

|[[Dulaglutide/ja]]

|[https://www.lillymedical.jp/ja-jp/trulicity トルリシティ](Trulicity) ([https://www.lillymedical.jp/ja-jp/assets/vaultpdf/565d081131f6d2bb133124f9c7cf107ef88de13b8b849a371c319d39b60caff9/トルリシティ（デュラグルチド）電子化された添付文書%20%7C%20医療関係者向け%20–%20日本イーライリリー株式会社 PI]) ([https://www.lillymedical.jp/ja-jp/assets/vaultpdf/cbb6477fcf44dc48299a00752139241dd2233803167c2977c7307fc27d85baca/トルリシティ（デュラグルチド）インタビューフォーム%20%7C%20医療関係者向け%20–%20日本イーライリリー株式会社 IF])

|販売

|[[Eli Lilly and Company]]

|

|-

|}

'''Glucagon-like peptide-1 (GLP-1) receptor agonists''', also known as '''GLP-1 analogs''', '''GLP-1DAs''' or '''incretin mimetics''', are a class of drugs that reduce blood sugar and [[energy intake]] by activating the [[glucagon-like peptide 1 receptor|GLP-1 receptor]]. They mimic the actions of the endogenous [[incretin]] hormone [[GLP-1]] that is released by the gut after eating.

@@ Line 3: / Line 3: @@
 {{Pathnav|Medication|Diabetes medication|frame=1}}
 {{Short description|Agonist of the GLP-1 receptor used in the treatment of type 2 diabetes}}
+{| class="wikitable sortable" style="width:100%"
+|-
+!一般名
+!先発名
+!class="unsortable"| 日本
+!創薬/開発
+!備考
+|-
+|[[Dulaglutide/ja]]
+|[https://www.lillymedical.jp/ja-jp/trulicity トルリシティ](Trulicity) ([https://www.lillymedical.jp/ja-jp/assets/vaultpdf/565d081131f6d2bb133124f9c7cf107ef88de13b8b849a371c319d39b60caff9/トルリシティ（デュラグルチド）電子化された添付文書%20%7C%20医療関係者向け%20–%20日本イーライリリー株式会社 PI]) ([https://www.lillymedical.jp/ja-jp/assets/vaultpdf/cbb6477fcf44dc48299a00752139241dd2233803167c2977c7307fc27d85baca/トルリシティ（デュラグルチド）インタビューフォーム%20%7C%20医療関係者向け%20–%20日本イーライリリー株式会社 IF])
+|販売
+|[[Eli Lilly and Company]]
+|
+|-
+|}
 '''Glucagon-like peptide-1 (GLP-1) receptor agonists''', also known as '''GLP-1 analogs''', '''GLP-1DAs''' or '''incretin mimetics''', are a class of drugs that reduce blood sugar and [[energy intake]] by activating the [[glucagon-like peptide 1 receptor|GLP-1 receptor]]. They mimic the actions of the endogenous [[incretin]] hormone [[GLP-1]] that is released by the gut after eating.